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Periodontitis is a chronic infection that results from the interaction of periodontopathogenic 
bacteria and host inflammatory and immune responses and is the most common bacterial 
infection worldwide. Estimates reveal that 10-15 % of adults have advanced periodontitis, 
and periodontal disease can contribute to widespread oral health dysfunction and enhanced 
susceptibility to other systemic diseases (Pussinen et al. 2007).  
Bacterial biofilms are regarded to be the primary aetiological factor in the initiation of 
gingival inflammation and subsequent destruction of periodontal tissues (Offenbacher 1996) 
and three major specific pathogens have been repeatedly identified as etiologic agents, 
namely Aggregatibacter (Actinobacillus) actinomycetemcomitans (Aa), Porphyromonas gingivalis 
(Pg) and Tannerella forsythia (Tf) (Socransky et al. 1998). Although chronic exposure to 
bacteria and their products is a prerequisite for gingival inflammation and periodontal 
tissue destruction to occur, the major causative factor of soft- and hard- tissue breakdown 
associated with periodontitis is currently attributed to the host’s immune-inflammatory 
response to bacterial challenge. Furthermore, the nature of the inflammatory response might 
determine the destructive character of the disease (Gemmell, Yamazaki, and Seymour 2002). 
The theoretical manner in which periodontal disease progresses has long been a subject of 
debate. It is currently agreed that destructive periodontal disease progresses by means of 
asynchronous bursts of activity (Haffajee and Socransky 1986). According to this theory, 
periodontal tissue support is lost during short, acute episodes followed by prolonged 
periods of quiescence (Reddy, Palcanis, and Geurs 1997). This model implies that etiologic 
factors involved in periodontal tissue destruction would change according to the sequential 
occurrence of episodes of disease activity and quiescence or remission. 
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Determination of periodontal diagnosis and the extent and severity of periodontal tissue 
damage through standard periodontal assessment has traditionally been based on an array 
of clinical measurements, including probing depth (PD), clinical attachment level (CAL), 
bleeding on probing (BOP), plaque index (PI) and radiographic findings. Though disease 
activity is generally associated to the loss of soft or hard tissue attachment to the tooth, 
recording of clinical attachment by periodontal probing at sequential examinations is the 
most common method to diagnose a progressive periodontal disease (Reddy, Palcanis, and 
Geurs 1997). However, clinical measurements provide information about past periodontal 
tissue destruction and do not elucidate the current state of the disease activity nor predict 
the future bone resorption (Armitage 2004). Thus, despite the value of these clinical 
methods, such techniques often result in inconsistent diagnoses, as well as an inability to 
reliably predict a patient´s response to treatment (Offenbacher et al. 2007). A reason for the 
limited success in predicting the future course of disease in some individuals is that the 
clinical phenotype does not reflect the underlying biologic processes that occur at the 
biofilm-gingival interface (Offenbacher et al. 2007). 
The biologic phenotype underlying chronic periodontitis, including the biofilm and the host 
response, tend to vary among individuals despite a similar clinical diagnostic category 
(Offenbacher et al. 2007). Consequently, disease screening should ideally be based on 
clinical determinations and the biologic phenotype (Page and Kornman 1997). Other 
associated factors include environmental exposures, as well as differences in genetic and 
possibly epigenetic composition (Page and Kornman 1997). 
The biological changes underlying the transition process from gingival health to early 
inflammatory changes involve local increase in vascular permeability, edema and the 
recruitment and activation of polymorphonuclear neutrophils (PMN) (Delima and Van 
Dyke 2003). Acquired immune response becomes involved once antigen-presenting cells 
interact with immunocompetent cells, such as T and B lymphocytes, leading to the 
expansion of antibody-secreting plasma cells and the development of the chronic lesion 
(Gemmell and Seymour 2004). Bacterial–host interactions at the biofilm–periodontium 
interface trigger the synthesis of cytokines and other inflammatory mediators that promote 
the release of enzymes and bone-associated molecules that finally induce the alterations of 
the connective tissue metabolism and the destruction of the tooth supporting alveolar bone 
(Bhavsar, Guttman, and Finlay 2007; Graves 2008; Houri-Haddad, Wilensky, and Shapira 
2007).  
In addition to local periodontal tissue involvement, chronic infection of the periodontium 
together with continuous up-regulation of pro-inflammatory responses and immune 
mediators may contribute to systemic sequel including diabetes, preterm delivery of low-
weight birth babies, lung inflammation, arthritis and cardiovascular diseases (CVD). In fact, 
numerous case-control and cohort studies have demonstrated that periodontitis patients 
exert increased risk for CVD, acute myocardial infarction (AMI), peripheral arterial disease 
and CVD, relative to patients with healthy periodontium (Mattila, Pussinen, and Paju 2005; 
Chen et al. 2008; Mattila et al. 2000; Alfakry et al. 2011; Persson et al. 2003). Although the 
associations of periodontal diseases with CVD have been investigated in several clinical 
studies the pathogenic mechanisms and links between both diseases are not completely 
clarified (Bahekar et al. 2007; Buduneli et al. 2011).  
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A major challenge in clinical periodontics is to find a reliable molecular marker of 
periodontal support loss with high sensitivity, specificity and utility (Buduneli & Kinane 
2011). Molecules derived from inflamed host tissue and pathogenic bacteria have the 
potential of being used as markers of periodontitis; however, molecular markers of bone 
resorption have advantages as they relate to specificity for bone, easy detection, pre-analytic 
stability and availability of sensitive and specific assays for detection (Forde et al. 2006). Up 
to now, at least 90 different components in gingival crevicular fluid (GCF) and oral fluids 
have been evaluated as possible biomarkers for diagnosis of periodontal disease and they 
can be divided into three major groups: (1) host derived enzymes and their inhibitors, (2) 
inflammatory mediators and host response modifiers, and (3) by-products of tissue 
breakdown, mainly of bone resorption (Lamster and Ahlo 2007). 
Recently, the use of oral fluids such as GCF, whole saliva and oral rinse as a means of 
evaluating host-derived products, as well as exogenous components (for instance: oral 
microorganisms and microbial products), has been suggested as potential sources and 
diagnostic markers, respectively for disease susceptibility (Sahingur and Cohen 2004; 
Buduneli and Kinane 2011). In fact, as whole saliva represents a pooled sample with 
contributions from all periodontal sites, analysis of biomarkers in saliva may provide an 
overall assessment of disease status as opposed to site-specific GCF analysis. This review 
will analyze the mechanisms involved in the breakdown of periodontal supporting tissues 
during chronic periodontitis, with a special focus on the role of T cells, matrix 
metalloproteinases (MMPs) and the development of chair side point-of-care diagnostic aids 
applicable to monitor both, periodontal and systemic inflammation. 
2. T cells and related cytokines 
Nowadays, it has been clearly demonstrated that increases in receptor activator of nuclear 
factor-kappa B ligand (RANKL) mRNA and protein levels in periodontal tissues stimulate 
the differentiation of monocyte-macrophage precursor cells into osteoclasts and the 
maturation and survival of the osteoclasts, leading to alveolar bone loss (Hernandez et al. 
2006; Ohyama et al. 2009; Nagasawa et al. 2007; Gaffen and Hajishengallis 2008; Crotti et al. 
2003; Hofbauer and Heufelder 2001; Kawai et al. 2006; Vernal et al. 2004). In this context, 
during inflammatory response characteristic of periodontitis, proinflammatory cytokines, 
such as interleukin (IL)-1┚, IL-6, IL-17, and tumor necrosis factor (TNF)-┙, can stimulate 
periodontal osteoblasts to express membrane-bound RANKL (Gaffen and Hajishengallis 
2008; Acosta-Rodriguez et al. 2007; Harrington, Mangan, and Weaver 2006; Mosmann and 
Sad 1996; Graves 2008). In addition to osteoblasts, RANKL is expressed by a number of 
other cell types, mainly CD4+ T lymphocytes (Kawai et al. 2006). 
CD4+ T lymphocytes represent one of the main components of the adaptive immune 
response and are the predominant cell type present in periodontitis gingival tissues 
(Hofbauer and Heufelder 2001; Kawai et al. 2006). After antigenic stimulation, naïve CD4+ T 
cells proliferate and may differentiate into distinct effector subsets, which have been 
classically divided on the basis of their cytokine production profiles into T helper (Th) 1 and 
Th2 cells (Mosmann et al. 1986). Th1 cells are characterized by the secretion of interferon 
(IFN)-┛, IL-2, IL-12, TNF-┙ and TNF-┚, and are involved in the eradication of intracellular 
pathogens. Conversely, Th2 cells are characterized by secretion of IL-4, IL-5, IL-6, IL-9 and 
IL-13, which are potent activators of B cells, are involved in the elimination of extracellular 
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microorganisms and parasitic infections, and are also responsible for allergic disorders 
(Mosmann and Sad 1996; Mosmann and Coffman 1989). 
More recently, two new subsets of CD4+ T lymphocytes have been characterized, the Th17 
subset, which follows different polarizing conditions and displays different functional 
activities than Th1 and Th2 cells, and the regulatory T (Treg) cell subset with suppressor 
functions (Mosmann and Sad 1996). Activated human Th17 cells are phenotypically 
identified as CCR2+CCR5- (Honma et al. 2007), whereas human memory CD4+ T cells 
producing IL-17 and expressing transcription factor related to orphan nuclear receptor C2 
(RORC2) mRNA are CCR6+CCR4+ (Acosta-Rodriguez et al. 2007). Th17 cells secrete several 
pro-inflammatory cytokines such as IL-6, IL-17, IL-21, IL-22, IL-23, IL-26, TNF-┙, and 
particularly RANKL (Liang et al. 2006; Harrington et al. 2005; Park et al. 2005). 
The role of Th17 cells in host defence against pathogens is just emerging, particularly  
on their destructive potential in periodontal diseases. Increased levels of IL-17 were 
detected in GCF and in biopsy samples from periodontal lesions, both at the mRNA  
and protein levels, in patients with chronic periodontitis and these increased levels have 
been associated to CD4+ T cells (Takayanagi 2005; Vernal et al. 2005; Takahashi et al. 
2005). Furthermore, RANKL was synthesized within periodontal lesions where IL-17  
was produced by activated gingival T cells (Takahashi et al. 2005; Kramer and Gaffen 
2007). These data are reinforced by the over-expression of RORC2 mRNA in active lesions 
from chronic periodontitis patients (Dezerega et al. 2010). Taken together, these data 
establish that Th17 cells represent the osteoclastogenic Th subset on CD4+ T lymphocytes, 
inducing osteoclastogenesis and bone resorption through synthesizing IL-17 and RANKL 
(Figure 1). 
Diverse studies have analyzed the concentrations of RANKL and osteoprotegerin (OPG) in 
GCF of periodontitis patients and healthy subjects. In general, they show great variation 
from study to study, but the ratio of RANKL/OPG has a consistent tendency to increase 
from periodontal health to periodontitis and to decrease following non-surgical periodontal 
treatment (Bostanci et al. 2008, Buduneli et al. 2009). In a cross-sectional study, Bostanci et al. 
(2008) quantified the RANKL and OPG levels in GCF from 21 healthy subjects, 22 gingivitis, 
28 chronic periodontitis (CP), 25 generalized aggressive periodontitis (GAgP) and 11 CP 
immunosuppressed patients, detecting that RANKL levels increased and OPG decreased in 
periodontitis patients compared with either gingivitis or healthy individuals, and concluded 
that RANKL/OPG ratio may predict disease occurrence (Bostanci et al. 2007). The same 
authors analyzed the GCF levels of TACE, an enzyme involved in the activation and 
secretion of RANKL from Th17 lymphocytes. They found that GCF TNF-alpha converting 
enzyme (TACE) levels were higher in periodontitis and TACE showed positive correlation 
with PD, CAL, and GCF RANKL concentration (Bostanci et al. 2008). In an intervention 
study (Buduneli et al. 2009), GCF levels of RANKL, OPG, and IL-17 were determined at 
baseline and also 4 weeks after completion of initial periodontal treatment in 10 smoker and 
10 non-smoker patients with chronic periodontitis. The authors concluded that neither 
smoking nor periodontal inflammation seemed to influence GCF RANKL levels in 
systemically healthy patients with chronic periodontitis. Smoking and non-smoking patients 
with chronic periodontitis were affected similarly by the initial periodontal treatment with 
regard to GCF IL-17 and OPG concentrations. 
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On the other hand, Buduneli et al. (2008) selected 67 untreated CP and 44 maintenance 
patients and established RANKL and OPG salivary levels, demonstrating that RANKL and 
OPG may be affected by smoking and significant differences between treated versus 
untreated CP were found. CP patients (35 subjects) and 38 periodontally healthy subjects 
were analyzed by Sakellari et al. (2008). The GCF levels of RANKL increased in CP patients 
compared with healthy controls and these higher levels correlated with detection of 
Treponema denticola and Porphyromonas gingivalis, but not with clinical parameters (Sakellari, 
Menti, and Konstantinidis 2008). Arikan et al. (2011) evaluated RANKL, OPG, ICTP, and 
albumin levels in peri-implant sulcular fluid samples from 18 root-type implants with peri-
implantitis in 12 patients and 21 clinically healthy implants in 16 other patients. The authors 
suggested that local levels of carboxyterminal telopeptide pyridinoline cross-links of type I 
collagen (ICTP) and OPG reflect an increased risk of alveolar bone loss around dental 
implants, and their local levels may help to distinguish diseased and healthy sites (Arikan, 
Buduneli, and Lappin 2011). Finally, Silva et al. (2008) performed a longitudinal follow-up of 
56 patients affected of moderate to severe CP until determination of disease progression, 
detecting higher RANKL, IL-1┚ levels and MMP-13 activity in active sites compared with 
inactive sites (Silva et al. 2008). Taken together, RANKL levels are promising as discloser of 
periodontal disease activity. Finally, carboxyterminal telopeptide pyridinoline cross-links of 
type I collagen (ICTP), released into the periodontal tissues as a consequence of MMP-
mediated alveolar bone resorption has been suggested to predict future bone loss, to 
correlate with clinical parameters and putative periodontal pathogens, and also to reduce 
following periodontal therapy, representing a potentially valuable diagnostic marker for 
periodontal disease (Giannobile, Al-Shammari, and Sarment 2003).  
3. Matrix metalloproteinases (MMPs): Destructive versus regulative roles 
Periodontal tissue homeostasis depends on the balanced and regulated degradation of 
extracellular matrix (ECM) proteins. In addition, the molecular organization of extracellular 
matrix is known to profoundly influence cell behavior. An unbalance in favor of collagenous 
matrix degradation will result in the loss of periodontal supporting tissue, the hallmark of 
chronic periodontitis (Reynolds and Meikle 1997). MMPs enclose a family of genetically 
distinct but structurally related zinc-dependent proteolytic enzymes that can synergistically 
degrade almost all extracellular matrix and basement membrane components and regulate 
several cellular processes, including inflammatory responses (McQuibban et al. 2001; 
McQuibban et al. 2002; Overall, McQuibban, and Clark-Lewis 2002). The 23 MMPs 
expressed in humans are classified based on their primary structures and substrate 
specificities into different groups that include collagenases (MMP-1, -8, -13), gelatinases 
(MMP-9, -2), membrane-type MMPs (MT-MMPs, MMP-14, -15, -16, -17, -24, -25) and other 
MMPs (Folgueras et al. 2004).  
MMPs share a basic structure composed of three domains, namely the pro-peptide, catalytic 
and the hemopexin-like domain; the latter is linked to the catalytic domain via a flexible 
hinge region. The proteolytic activity of MMPs is subjected to a complex regulation that 
involves three major steps (Kessenbrock, Plaks, and Werb 2010): 1) gene expression, 2) 
conversion of zymogen to active enzyme and 3) specific inhibitors. MMPs are initially 
synthesized as pro-enzymes which are enzymatically inactive because of the interaction 
between the cysteine residue of the prodomain with the zinc ion of the catalytic site, known 
as cysteine switch. Disruption of this interaction through proteolytic removal of the 
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prodomain or chemical modification results in enzyme activation. There are several 
proteinases that mediate MMP activation, including plasmin, furin and active MMPs that 
assemble in enzymatic amplifying loops. Once activated, the most important physiological 
inhibitors are tissue inhibitors of MMPs (TIMPs) -1, -2, -3 and -4 (Folgueras et al. 2004). 
Herein, the pathophysiological significance of increased MMP expression in periodontitis 
will rely ultimately on the presence of endogenous inhibitors and activating enzymes that 
will determine overall MMP activity (Sorsa, Mantyla et al. 2011; Buduneli and Kinane 2011). 
MMPs, especially those with collagen-degrading properties, such as MMP-8, MMP-13 and 
MMP-9, have been recognized as the key proteases involved in destructive periodontal 
diseases and have widely been demonstrated in inflamed periodontal tissues and in oral 
fluids in association with supporting tissue loss by different analytic methods, including 
ELISA, immunofluorometric assays (IFMA), checkerboard method and immuno blots, 
(Folgueras et al. 2004; McQuibban et al. 2001; McQuibban et al. 2002; Overall, McQuibban, 
and Clark-Lewis 2002; Sorsa et al. 2006; Sorsa, Tjaderhane, and Salo 2004). All human MMPs 
are known to exist in multiple forms, i.e. latent pro-forms, active or activated forms, 
fragmented species, complexed species and cell-bound forms (Sorsa, Mantyla et al. 2011). 
The expression of different MMP isoforms in oral fluid samples can be analyzed with 
western immunoblotting, whereas a limitation of conventional MMP immunoassays used in 
periodontal research, such as ELISA, is that they do not differentiate these forms.  
MMP-8 is mainly produced by neutrophils (PMN), but it can also be expressed by gingival 
fibroblasts, endothelial cells, epithelial cells, plasma cells, macrophages and bone cells 
(Heikkinen et al. 2010). MMP-8 is the major collagenolytic MMP in gingival tissue and oral 
fluids and elevated levels have been associated with the severity of periodontal 
inflammation and disease (Mantyla et al. 2006), whereas basal physiologic levels might be 
associated to tissue homeostasis and even to be protective against disease (Kuula et al. 2009). 
Among total collagenases in GCF, MMP-8 accounts for about 80%, whereas MMP-13, for up 
to 18% and MMP-1 is seldom detected (Golub et al. 2008).  
MMP-13 has been identified in gingival sulcular epithelium, fibroblasts, macrophages, 
plasma cells and osteoblasts (Tervahartiala et al. 2000; Hernandez et al. 2006; Rydziel, 
Durant, and Canalis 2000). MMP-13 has been implicated in bone resorptive process, along 
with MMP-9 (Hill et al. 1995; Hill et al. 1994; Holliday et al. 1997). Total MMP-13 levels, as 
well as proenzyme (~60 kDa) and its active forms (~45-50 kDa), have been shown to increase 
in chronic periodontitis versus healthy sites in GCF in association with clinical periodontal 
parameters (Tervahartiala et al. 2000; Kiili et al. 2002; Ilgenli et al. 2006).  
MMP-9 is the major gelatinase in oral fluids (Makela et al. 1994). As MMP-8, MMP-9 is 
present in granules of PMN and it is also expressed in a variety of other cell types, including 
resident periodontal cells, such as fibroblasts, keratinocytes and infiltrating leukocytes, like 
macrophages and plasma cells (Sorsa, Tjaderhane, and Salo 2004; Makela et al. 1994). Total 
MMP-9 levels and its active form have been demonstrated to significantly increase with 
periodontal inflammation in comparison to controls, composed of gingivitis and healthy 
subjects, and to drop along with inflammation  after periodontal therapy (Makela et al. 1994; 
Bildt et al. 2008) (Figure 1). 
Genetic variations can influence MMP transcription levels and protein synthesis. Despite the 
genetic background of periodontal diseases and the wide involvement of MMP-9, MMP-8 
and MMP-13, MMP gene polymorphisms studied in different ethnic populations have not 
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been able to conclude specific associations with the susceptibility to develop periodontitis or 
disease severity. Similar allele and genotype frequencies have been demonstrated at the 
MMP-9 -1562 and –R+279Q polymorphic sites between periodontitis patients and healthy 
controls, despite the presence of significantly increased protein levels in serum and saliva of 
diseased subjects (Isaza-Guzman et al. ; Loo et al. 2011; de Souza et al. 2005; Chen et al. 2007; 
Gurkan et al. 2008). Nevertheless, the -1572T allele might be associated with a severe form of 
chronic periodontitis in men (Holla et al. 2006). Similarly, no differences in MMP-13- 77 
A/G and -11 A /12 A polymorphic sites have been found for periodontitis patients (Pirhan 
et al. 2009), whereas no genetic studies are currently available for MMP-8.  
Regarding, especially MMP-8, -9 and -13, it is noteworthy that clinical progression of 
periodontitis in active versus inactive sites and/or patients has been repeatedly demonstrated 
to be reflected as pathologically excessive elevation of either active MMP forms, i.e. conversion 
of latent pro-form to active form, or enzyme activity assessed by functional assays, i.e. total 
activated enzyme unbound to TIMPs, in GCF/peri-implant sulcular fluid (PISF), mouth-rinse 
and saliva samples collected from periodontitis/peri-implantitis sites and patients (Hernandez 
et al. 2010; Hernandez Rios et al. 2009; Sorsa, Mantyla et al. 2011). Regarding 
periodontitis/peri-implantitis progression in disease-active sites, pro-MMP-8, -9 and -13 have 
been demonstrated to be activated by independent and/or co-operative cascades involving 
other host proteinases (MMPs, serine proteases), reactive oxygen species and/or microbial 
proteases (Buduneli et al. 2011; Hernandez et al. 2010; Hernandez Rios et al. 2009). GCF 
collagenase activity and MMP-8 activation are also found to correlate with the levels of type I 
collagen breakdown fragments overcoming the protective shield provided by TIMP-1 
(Reinhardt et al. 2010; Sorsa, Mantyla et al. 2011). Similarly, MMP-13 activity and ICTP have 
shown to increase in active sites compared with inactive sites from progressive periodontitis 
patients or healthy subjects (Hernandez Rios et al. 2009). 
Clinical trials testing subantimicrobial dose doxycycline (SDD, synthetic FDA-approved 
MMP-inhibitor) medication have repeatedly reported an association between improvement 
of clinical parameters and reduction of GCF and serum MMP-8, -13 and -9 activation and 
levels (Reinhardt et al. 2010, Sorsa et al. 2011). It is possible to monitor the effect of 
periodontal treatment and adjunctive SDD medication by point-of-care MMP-8 
immunoassays (Sorsa, Tervahartiala et al. 2011). 
MMPs can also act by regulating many other MMP activation cascades. This later role could 
even be more significant in periodontal tissue destruction than direct collagenolytic activity, 
in a way that a subtle change in regulating MMPs might result in widespread MMP 
activation and consequent tissue destruction (Folgueras et al. 2004; Hernandez et al. 2010). 
MMP-14 activates the collagenases MMP-8 and MMP-13 in vitro (Holopainen et al. 2003; 
Folgueras et al. 2004; Han et al. 2007; Dreier et al. 2004; Knauper et al. 1996). Several studies 
using experimental models associate MMP—14, -13, -9 and -2 over expression with bone 
resorption, and the inhibition of bone loss by the addition of an MMP inhibitor (de Aquino 
et al. 2009; Rifas and Arackal 2003; Garlet et al. 2006; Cesar Neto et al. 2004; Trombone et al. 
2009). In vitro studies have revealed that MMP-13 might initiate bone resorption by 
generating collagen fragments that can activate osteoclasts (Holliday et al. 1997) and 
proMMP-9 (Knauper et al. 1997). Active MMP-9 in turn, further digests denatured collagen 
derived from MMP-13 activity (Hill et al. 1995), is thought to act over preosteoclast 
recruitment to sites for osteoclast differentiation and bone resorption, and activates 
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proMMP-13 and proMMP-2. On the other hand, proMMP-13 can also be activated by active 
MMP-14, MMP-2 and MMP-13 in vitro (Knauper et al. 1996). Nevertheless, whether these 
enzymes proteolytically interact in vivo is not clear, yet. 
Adding of recombinant MMP-13 to gingival tissue from chronic periodontitis patients has 
been reported to result in elevated proMMP-9 and proMMP-2 activation rates, but only the 
former was significant. Furthermore, addition of MMP-13 specific synthetic inhibitor CL-
82198 prevented proMMP-9 activation (Hernandez Rios et al. 2009). These results suggest an 
activation cascade involving MMP-13, MMP-9 and possibly MMP-2 in periodontitis 
progression. Higher MMP-14 levels have also been found in gingival tissue from 
periodontitis subjects compared to healthy gingiva (Oyarzun et al. 2010) and soluble forms 
of MMP-14 have been described in periodontitis GCF (Tervahartiala et al. 2000), showing a 
trend to be higher in active sites in comparison to inactive ones in patients with progressive 
periodontitis (Hernandez et al. 2010). Moreover, a positive correlation between active MMP-
14 and active MMP-13 in periodontitis GCF was found, suggesting proteolytic activation to 
occur in vivo (Hernández et al. 2011). Thus, this novel proteolytic cascade could perpetuate 
periodontal soft and hard tissue destruction in a feed forward manner. Conversely, MMP-14 
has been inversely correlated to MMP-8 in GCF from active sites in progressive 
periodontitis, and thus this proteolytic activation mechanism might be of minor importance 
in disease progression (Hernandez et al. 2010; Hernandez, Dutzan et al. 2011). 
MMPs can also regulate many biological processes through limited proteolysis of matrix and 
non-matrix bioactive molecules, such as immune-inflammatory response and wound healing, 
among others, through either 1) hydrolysis of extracellular matrix to allow cell migration, 2) 
cleavage of binding proteins and releasing of soluble bioactive molecules from extracellular 
matrix reservoir or cell compartment and 3) by processing bioactive molecules, modifying 
their biological activity (Korpi et al. 2009; Lin et al. 2008; Tester et al. 2007; Van Den Steen et al. 
2003; Van Lint et al. 2005; Gutierrez-Fernandez et al. 2007; Hernandez et al. 2011).  
It has been recently reported that Porphyromonas gingivalis-induced experimental 
periodontitis in MMP-8 knock-out mouse model resulted in a more severe disease 
phenotype and reduced levels of mouse lipopolysaccharide (LPS)-induced CXC chemokine 
(LIX/CXCL5) than their wild type counterparts (Kuula et al. 2009; Hernandez et al. 2011). 
LIX/CXCL5 and its human homologue, granulocyte chemotactic protein-2 (GCP-2/CXCL6) 
have been proposed to regulate neutrophil influx to periodontal tissues at the oral interface, 
where they represent the first line of defense against periodontal pathogens (Kebschull et al. 
2009; Hernandez et al. 2011). Accordingly, several studies support a role for MMP-8 in PMN 
trafficking in different inflammation models. LIX/CXCL5 levels have also shown to 
diminish in other MMP-8 knock-out mouse models (Gutierrez-Fernandez et al. 2007; 
Nilsson, Jonsson, and Dabrosin 2009), such as TNF-induced lethal hepatitis model (Van Lint 
et al. 2005), and reduced levels of transforming growth factor (TGF)-┚1 in MMP-8-/- mice 
have been associated with PMN impaired infiltration and wound healing (Gutierrez-
Fernandez et al. 2007). All these potential regulatory mechanisms together or alone may lead 
to an impaired PMN influx to the sites of inflammation in MMP-8 deficient mice and alter 
disease expression. Similarly, MMP-9 activity was shown to down regulate TGF-┚1 protein 
levels in breast cancer cells exposed to tamoxifen (Nilsson, Jonsson, and Dabrosin 2009; 
Balbin et al. 2003). In addition, recent evidence supports that MMP-13 might also influence 
soluble protein levels from RANKL/OPG axis (Nannuru et al. 2010). 
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Fig. 1. The host response during periodontitis with emphasis on T cells and matrix 
metalloproteinases (MMPs) in periodontal tissue breakdown. As result of chronic stimuli from 
periodontopathogenic biofilm an immune-inflammatory response is established in periodontal 
tissues. The major features are the synthesis of inflammatory cytokines, such as IL-1┚, IL-12, 
TNF-┙ and pathologically elevated matrix metalloproteinases (MMPs) synthesis and 
activation, specially MMP-8, MMP-9, and MMP-13. These MMPs degrade extracellular matrix, 
particularly collagen I, and they also influence periodontal immune-inflammatory response 
through limited proteolysis. Th17 cells may be activated as consequence of antigen 
presentation and contribute to bone destruction by secreting IL-17 and RANKL. IL-17 
increases the inflammatory response and induces RANKL expression by osteoblastic cells. 
RANKL induces an increment in the osteoclast differentiation/maturation and alveolar  
bone resorption. MMP-13 produced by osteoblasts and MMP-9 from osteoclasts participate  
in the degradation of organic bone matrix. IL: interleukin; MMP: matrix metalloproteinase; 
TNF: tumor necrosis factor; TGF: transforming growth factor; OC: Osteoclast;  
APC: Antigen presenting cell; PMN: neutrophil; MO: macrophage; OBL: osteoblast. 
4. Oral fluid chair-side point-of-care technologies and their systemic 
applications 
Oral fluids [GCF, saliva, mouth-rinse, PISF] contain various molecular mediators often 
called biomarkers that reflect several physiological and pathological conditions. Qualitative 
and quantitative changes in the oral fluid biomarkers have been found to exert significance 
in the adjunctive diagnostics and treatment of various oral and systemic disorders. 
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Periodontal diseases are reflected in oral fluids as elevated levels of host cell-derived tissue 
destructive proteolytic enzymes, i.e. MMP-8, -9 and  -13 , neutrophil elastase , ┙2-macroglobulin, 
oxygen radical producer myeloperoxidase (MPO), pro-inflammatory mediators, (C Reactive 
Protein (CRP), IL-1┚, TNF-┙, macrophage inflammatory protein -1) and bone remodeling 
markers (alkaline phosphatase, ICTP, RANKL, osteoprotegrin and osteocalcin). Among these 
periodontitis-related oral fluid biomarkers, especially MMP-8, -9 and -13, as well as MPO are 
potential candidates for chair-side point-of-care oral fluid assays (Hernandez et al. 2010; 
Leppilahti et al. 2011; Sorsa, Tervahartiala et al. 2011). Low GCF volume and low biomarker 
levels in all oral fluids are characteristic during periodontal health, but the biomarker contents 
increase along with the severity of periodontal inflammation (Pussinen et al. 2007).  
GCF, salivary and mouth-rinse biomarker analysis can provide adjunctive information for 
health care professionals alongside traditional oral clinical examination whether periodontal 
disease is present, whether treatment or medication is required or if the treatment or 
medication has been effective. GCF represents site specific analysis of studied biomarkers 
and volume. However, molecular analysis of GCF elution can be time consuming while 
most of the GCF analytic assays are laboratory based and usually cannot be performed in a 
chair-side manner. These procedures, as well as GCF sampling, are technically demanding 
and the GCF volume can be very small (1-5 µl). Despite these apparent diagnostic and 
technical disadvantages, GCF is still considered as a candidate potential oral fluid for the 
development of adjunctive non-invasive chair-side point of-care diagnostic technology 
(Sorsa et al. 1999; Sorsa et al. 2006; Sorsa, Tjaderhane, and Salo 2004; Mantyla et al. 2006; 
Mantyla et al. 2003; Munjal et al. 2007), especially because tissue destructive MMPs and their 
bioactive regulators can conveniently be measured by distinct catalytic and non-catalytic 
immunoassays from GCF (Sorsa et al. 2010).  
In relation to GCF, collection of salivary and mouth-rinse samples is more convenient, 
practical, rapid and non-invasive and requires neither professional stuff nor specific 
materials. It could even be carried out by patients themselves. Saliva and mouth-rinse 
represent a pooled sample from all periodontal sites providing an overall assessment of 
periodontal disease and health at subject level. Whole saliva can be affected by molecular 
constituents and cellular remnants from other oral niches, as well as systemic conditions 
(Buduneli et al. 2011; Buduneli and Kinane 2011) which should be considered when it is 
used for diagnostics.  
MMP-8 or collagenase-2/neutrophil-collagenase is the major type of interstitial collagenase 
present in human periodontitis-affected gingival tissue, GCF, PISF, saliva and mouth-rinse 
samples (Sorsa et al. 2006). Antibodies applied in the immunoassays for the detection of 
MMPs and their regulators affect the measurement outcome (Leppilahti et al. 2011; Gursoy 
et al. 2010; Sorsa et al. 2010; Sorsa, Mantyla et al. 2011). Nevertheless, especially MMP-8 
immunoassays and activity assays targeting PMN-type MMP-8 isoenzyme species in oral 
fluids have been found to be useful to differentiate periodontitis/peri-implantitis and 
gingivitis sites/patients as well as healthy sites/subjects (Mantyla et al. 2006; Mantyla et al. 
2003; Hernandez et al. 2010; Sorsa et al. 2010; Sorsa, Mantyla et al. 2011). Although 
periodontal clinical examination is necessary and cannot be substituted by any other means 
in periodontal diagnostics, biomarker testing could give relevant clinical adjunctive 
information about the individual’s host response levels, although there is no known normal 
range at present. 
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Selective antibodies for detection of active MMP-8 in oral fluids have been utilized as 
adjunctive diagnostic point-of-care/chair-side tests identifying sites susceptible for 
periodontitis progression and periodontitis affected patients (Leppilahti et al. 2011; Mantyla 
et al. 2006; Sorsa, Mantyla et al. 2011; Sorsa, Tervahartiala et al. 2011). We have recently 
investigated levels of GCF MMP-8 with two different chair-side (dentoAnalyzer by 
dentognostics GmbH and MMP-8 specific chair-side dip-stick test) and two laboratory 
methods (immunofluorometric assay, IFMA, and commercial ELISA) (Sorsa et al. 2010). 
IFMA, dentoAnalyzer and MMP-8 specific chair-side dip-stick test results were well in line. 
Results obtained with MMP-8 commercial ELISA kit were not in line with recordings by 
other methods. Both IFMA and dentoAnalyzer device detected the GCF samples’ MMP-8 
levels with equal reliability. The chair-side dip stick test results were in line with results 
with these two other methods but the capability of the dip-stick test to differentiate the 
sample levels were rougher. The chair-side dip-stick test detected especially the sites with 
high MMP-8 levels. 
The differences between dentoAnalyzer, IFMA, dipstick and commercial ELISA MMP-8 
analysis of GCF levels can be, at least in part, explained by the evidently different 
specificities and sensitivities between antibodies used in these assays. DentoAnalyzer, IFMA 
and dipstick assays use same antibody (Hanemaaijer et al. 1997). Regarding serum and 
plasma MMP-8 determinations by using both IFMA and commercial ELISA, significantly 
higher serum MMP-8 values were recorded relative to plasma, and the differences were 
most notable with high serum MMP-8 concentrations as measured using IFMA (Tuomainen 
et al. 2008; Emingil et al. 2008). The antibody used in dentoAnalyzer, IFMA and dip-stick 
exerts high sensitivity to both PMN- and fibroblast-type MMP-8 isotypes and especially 
their active forms (Hanemaaijer et al. 1997; Sorsa et al. 1999). 
Although several studies have demonstrated the central role of MMP-8 in periodontitis, it 
has not been shown that it is predictive of disease progression, i.e. that the increased MMP-8 
concentration in GCF would precede the occurrence of attachment loss (AL). This problem 
arises from the nature of periodontitis and from the accuracy of diagnosing a site as 
progressing with clinical or radiological methods. Disease progression is regarded to be 
mostly episodic, occurs only infrequently and is slow in most chronic periodontitis patients. 
During a study period, it is likely that only a small number of sites with AL can be 
confirmed. Additionally, only a small group of periodontitis patients manifest multiple 
progressing sites (Chambers et al. 1991; Mantyla et al. 2006). In our previous study, we 
could not make a conclusion about the predictive value of MMP-8 testing (Mantyla et al. 
2006). However, we concluded that repeatedly elevated GCF MMP-8 levels indicate the sites 
at risk of periodontal AL and that testing of MMP-8 site specifically from GCF is a valuable 
diagnostic aid which supplements the traditional methods especially from selected sites in 
the maintenance phase of periodontitis patients who are at continuous risk for periodontitis 
recurrence. Periodontitis patients’ GCF MMP-8 levels decrease after conventional 
periodontitis hygiene phase treatment. However, the levels remain higher than in gingivitis 
patients’ or in periodontally healthy subjects’ GCF (Mantyla et al. 2003). This is valid also in 
periodontitis patients’ shallow sites, as well as sites with no attachment loss, and tells about 
the elevated basic host response of periodontitis subjects (Mantyla et al. 2006; Mantyla et al. 
2003) (Figure 2). 
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Fig. 2. MMP-8 levels in gingival crevicular fluid from subjects with moderate and severe 
chronic periodontitis. The box plot shows MMP-8 IFMA levels (µg/l) from patients 
suffering of moderate chronic periodontitis (4 patients, 34 sites) and severe chronic 
periodontitis (10 patients, 81 sites). Same sites from each patient were analyzed before any 
periodontitis treatment (baseline), one month after treatment (scaling and root planing), and 
with two-month interval during the maintenance phase (2-10 month). From each patient 
both shallow and deep sites at baseline were included into analyzed sites. The figure shows 
that GCF MMP-8 levels decrease in both groups after treatment but remain at comparatively 
high levels in severe periodontitis at each point in time indicating the higher level of host 
response. Box plots also show the wide ranges of MMP-8 levels, which are typical for 
biomarkers, and ranges become wider with the severity of the disease. 
Based on other recent findings the salivary and oral rinse chair-side sample analysis of MMP-8 
can be clinically useful in rough screening to identify individuals with periodontitis or to 
analyze the individual level of host response. Simultaneous analysis of MMP-8 and TIMP-1 
could be beneficial (Leppilahti et al. 2011). The oral fluid testing could give valuable additional 
information about the control of inflammation which today is based on the clinical findings, that 
is shallower or eliminated periodontal pockets and less bleeding on probing. Salivary and oral 
rinse sample analysis may be useful in defining the optimal period between periodontal 
maintenance visits after active periodontal treatment. During the active treatment phase it could 
be possible to monitor the decrease of salivary and oral rinse MMP-8 levels; at the end of the 
active treatment phase it would show the individual optimal biomarker level to keep the host 
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response in control. At best the biomarker level could be monitored by screening home self-test 
to indicate when the cut-off for possibly unsafe biomarker level is reached. Also the effect of 
MMP-8 inhibiting SDD  medication could be monitored by analyzing the salivary and oral rinse 
MMP-8 levels to find out when a possible break in medication would be possible or when the 
medication should be taken again (Golub et al. 2008; Reinhardt et al. 2010). Screening type 
testing from saliva or oral rinse would also be applicable for differentiation of the borderline 
between gingivitis and peridontitis, because gingivitis patients’ MMP-8 levels are shown to be 
significantly lower than periodontitis patients’ levels (Mantyla et al. 2003). Thus, the levels 
repeatedly approaching to those of peridontitis could be used to indicate patients at risk. 
The point-of-care MMP-8 immuno-technologies from oral fluids and serum/plasma can be 
well adapted for monitoring of systemic inflammation (Tuomainen et al. 2007; Buduneli and 
Kinane 2011). In this regard, the elevation of serum and plasma MMP-8 has been associated 
with AMI, CVD and sepsis (Buduneli et al. 2011; Lauhio et al. 2011; Sorsa, Tervahartiala et 
al. 2011). Furthermore, a recent study on salivary MMP-8 assessed by Western immunoblot 
analysis in patients with or without acute myocardial infarction revealed that elevated 
salivary MMP-8 activation is associated with AMI (Buduneli et al. 2011). Moreover, elevated 
serum MMP-8 levels have recently been demonstrated to be associated with total outcome 
in a multicentre and prospective cohort study in sepsis; serum MMP-8 levels were 
significantly higher among non-survivors that among survivors. Thus elevated oral fluid 
and serum MMP-8 can be considered as a potential risk factor for systemic diseases such as, 
but not limited to, CVD, sepsis, diabetes, stroke, arthritis and pulmonary diseases (Kardesler 
et al. 2010; Biyikoglu et al. 2009; Buduneli et al. 2011; Ozcaka et al. 2011). In addition, oral 
MMP-8 activation as a consequence of AMI may contribute to progression of periodontitis 
and/or oral discomfort. However, oral fluid point-of-care diagnostics contains many 
potential confounders. The various medications together with systemic diseases (mental 
disorders / psychiatric diseases, nephritic syndrome) can affect the levels of potential 
periodontitis and CVD biomarkers in saliva and serum/plasma (Alfakry et al. 2011; Sorsa, 
Tervahartiala et al. 2011; Buduneli et al. 2011). Accordingly, the beneficial and reducing 
effects of lymecycline (a tetracycline-derivate) on serum MMP-8 levels could be monitored 
by MMP-8 immunoassay in reactive arthritis (Lauhio et al. 2011). In fact, serum MMP-8 
levels may reflect defensive molecular processes in certain malignancies (Korpi et al. 2008) 
and also HIV-infection has been found to affect the level of MMPs and their regulators in 
oral fluid and serum/plasma (Mellanen et al. 2006). 
5. Concluding remarks 
Periodontal tissue destruction derived from chronic periodontitis occurs as consequence to 
the activation of immune-inflammatory response of the host to bacterial challenge. Major 
events comprise pro-inflammatory cytokine production and collagenolytic MMPs, such as 
MMP-8, MMP-13 and MMP-9 leading to soft periodontal tissue breakdown. Activation of 
Th17 subset of T lymphocytes will induce the synthesis of IL-17 and RANKL. These 
cytokines along with bone MMPs, will lead ultimately to octeoclastogenesis and alveolar 
bone resorption. Qualitative and/or quantitative changes in  oral fluid biomarkers might be 
useful as adjunctive diagnostics and treatment of periodontitis. Among them, it appears that 
MMP-8 point-of-care diagnostics exert a huge potential in oral diagnostics and forms a 
diagnostic link from oral cavity to systemic inflammatory conditions. 
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